Monopar Therapeutics short interest in 2023
In 2023, Monopar Therapeutics's disclosed short interest ran from 0.10% of shares outstanding on 13 Jan 2023 to 0.71% on 29 Dec 2023, a change of +0.61 percentage points. The year's high was 1.26% on 15 Nov 2023 and its low 0.10% on 13 Jan 2023, averaging 0.56% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.96 days on 28 Apr 2023. Full history: Monopar Therapeutics.
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 0.10% (13 Jan 2023)
- End of year
- 0.71% (29 Dec 2023)
- Change
- +0.61 pp
- High
- 1.26% (15 Nov 2023)
- Low
- 0.10% (13 Jan 2023)
- Average
- 0.56%
- Highest days to cover
- 4.96 (28 Apr 2023)
- SEC filings marked
- 8
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 0.10% | 1.99 | |
| 15 Feb 2023 | 0.25% | 1.00 | |
| 28 Feb 2023 | 0.31% | 2.72 | |
| 15 Mar 2023 | 0.50% | 4.33 | |
| 31 Mar 2023 | 0.70% | 1.06 | 10-K filed, results (8-K) |
| 14 Apr 2023 | 0.47% | 2.58 | |
| 28 Apr 2023 | 0.57% | 4.96 | |
| 15 May 2023 | 0.60% | 4.01 | 10-Q filed, results (8-K) |
| 31 May 2023 | 0.64% | 1.00 | |
| 30 Jun 2023 | 0.88% | 1.26 | |
| 31 Jul 2023 | 0.43% | 1.00 | |
| 31 Aug 2023 | 0.68% | 1.71 | 10-Q filed, results (8-K) |
| 15 Sep 2023 | 0.46% | 2.63 | |
| 29 Sep 2023 | 0.26% | 2.20 | |
| 13 Oct 2023 | 0.33% | 2.35 | |
| 31 Oct 2023 | 0.35% | 4.05 | |
| 15 Nov 2023 | 1.26% | 1.00 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 1.14% | 2.16 | |
| 15 Dec 2023 | 0.47% | 1.00 | |
| 29 Dec 2023 | 0.71% | 1.00 |
See also: Monopar Therapeutics's full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.